SCHEMBL6902895

SCHEMBL6902895

Nc1ncnc2c1ncn2[C@@H]1O[C@H](C(O)C(=O)O)[C@@H](O)[C@H]1O.[NaH]

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 5/20 0.67
HIF1A Q16665 1/20 0.67
TMEM97 Q5BJF2 1/20 0.67
SIGMAR1 Q99720 1/20 0.67
ADORA2A P29274 3/20 0.64
ADORA2B P29275 3/20 0.64
HSP90B1 P14625 2/20 0.64
ADORA3 P0DMS8 3/20 0.62
KMT2A Q03164 2/20 0.62
ADORA1 P30542 2/20 0.62
TSHR P16473 1/20 0.62
LMNA P02545 1/20 0.62
THRB P10828 1/20 0.62
BLM P54132 1/20 0.62
HSP90AA1 P07900 1/20 0.62
DOT1L Q8TEK3 2/20 0.61
DPP4 P27487 1/20 0.61
MEN1 O00255 1/20 0.61
SLC28A1 O00337 1/20 0.61
MAP3K7 O43318 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6902907 1.00 AHCY (0.67) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL1757011 0.99 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL29385449 0.99 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL2117335 0.99 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL6902911 0.98 AHCY (0.67) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL30139993 0.90 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL4520806 0.90 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL4520798 0.90 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL30139992 0.90 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL5620791 0.89 AHCY (0.58) AHCYHIF1ATMEM97SIGMAR1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482977-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed
WO-2003074083-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP AHCY 62/4885HIF1A 3905/4885TMEM97 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.